Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

In Kids with Group A Strep, Do Steroids Shorten Illness Duration, Severity?

By Landon Jones, MD and Richard M. Cantor, MD, FAAP, FACEP | on November 18, 2020 | 1 Comment
Kids korner
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
shut by Landon Jones, MD, and Richard M. Cantor, MD, FAAP, FACEP The best questions often stem from the inquisitive learner. As educators, we love, and are always humbled by, those moments when we get to say, “I don’t know.” For some of these questions, you may already know the answers. For others, you may never have thought to ask the question. For all, questions, comments, concerns, and critiques are encouraged. Welcome to the Kids Korner. Antibiotics for Strep Question 1: In children with group A strep pharyngitis, what benefit(s) does antibiotic treatment offer? While a potentially reasonable argument may be made about deferring antibiotic treatment of GAS-positive pharyngitis, is antibiotic treatment beneficial? To begin, an earlier RCT by Nelson evaluated 35 children ages 5–11 years with GAS confirmed by culture and randomized patients to penicillin (PCN) treatment or placebo.1 Follow-up visits occurred at 48 hours. Patients treated with PCN had a significantly shorter duration of fever at follow-up, with 28 percent of placebo patients having persistent fever >48 hours but no treated patients having persistent fever (P=0.031). At 48-hour follow-up, children receiving PCN also had significantly shortened times until improved (P=0.008) and until well (P=0.022). A similar shortened duration of fever at 48 hours was seen in another RCT by Pichichero et al.2 A Cochrane meta-analysis by Spinks et al evaluated 27 trials with 12,835 total cases.3 This included both adults and children and included patients with the diagnosis of sore throat, not specifically GAS. Regarding antibiotics versus placebo, the risk ratio of the incidence of developing the secondary complication of otitis media within 14 days following GAS pharyngitis antibiotic treatment was 0.30 (95 percent CI, 0.15–0.58; 11 studies), suggesting that antibiotic therapy decreased the incidence of the complication of otitis media. Similarly, the risk ratio of the incidence of developing “quinsy”—meaning peritonsillar abscess or retropharyngeal abscess—within two months following GAS antibiotic treatment was 0.15 (95 percent CI, 0.05–0.47; eight studies). Lastly, the risk ratio of the incidence of developing acute rheumatic fever (ARF) within two months was 0.27 (95 percent CI, 0.1–0.50; 14 studies). While ARF is traditionally rare in Western countries (
Shutterstock.com

The best questions often stem from the inquisitive learner. As educators, we love, and are always humbled by, those moments when we get to say, “I don’t know.” For some of these questions, you may already know the answers. For others, you may never have thought to ask the question. For all, questions, comments, concerns, and critiques are encouraged. Welcome to the Kids Korner.

You Might Also Like
  • Myths in Emergency Medicine: 24-Hour Treatment with Antibiotics for Strep Throat
  • In Kids with Group A Strep, What Benefit(s) Do Antibiotics Offer?
  • Is Dexamethasone Helpful for Treating Pharyngitis?
Explore This Issue
ACEP Now: Vol 39 – No 11 – November 2020

Question 2: In children with confirmed group A strep pharyngitis, do steroids shorten duration and severity of the illness?

With winter beginning, strep throat cases will start to ramp up. This month, we will look at group A strep (GAS) pharyngitis—not the broader bucket of “exudative pharyngitis” that may or may not include GAS.

We were able to find five randomized controlled trials (RCTs) that included GAS children receiving steroids.1–5 The mean ages (in years) of patients in these five studies that included children were 26.4, 28.1, 9.7, 11.9, and 7.7, respectively—meaning the first two studies predominantly included adults. We will therefore focus on the remaining three RCTs. (This is Kids Korner, folks.)

A 2003 RCT by Bulloch et al included 184 children ages 5–16 years and evaluated adjuvant oral dexamethasone in both GAS-positive (n=85) and GAS-negative (n=99) patients.3 Consecutive children at a single pediatric emergency department presenting with symptoms of pharyngitis were assessed and received a rapid strep test. GAS-positive and -negative patients were then randomized to receive adjuvant oral dexamethasone 0.6 mg/kg (maximum of 10 mg) or placebo. All GAS-positive patients received antibiotics. Exclusions included children who were immunocompromised, had an abscess, or had corticosteroid exposure during the preceding two months, as well as pregnant patients, patients with diabetes, or those already taking antibiotics. Follow-up was at 24 hours, 48 hours, and one month.

Pain intensity in all groups was not significantly different. Overall, there was no statistically significant change in time to complete pain relief between dexamethasone and placebo groups—independent of whether the patient was GAS positive or negative. In the GAS-positive group, though, there was a significantly shorter mean time to clinically significant pain relief in the dexamethasone group (6.0 hours versus 11.5 hours; P=0.02). This was not found in the GAS-negative group (P=0.32).

To summarize, GAS-positive patients receiving dexamethasone had faster initial pain relief (about six hours) but similar times to complete pain relief when compared with placebo. The authors describe this faster pain relief as “of marginal clinical importance.”

The second RCT by Olympia et al evaluated a convenience sample of 125 children ages 5–18 years who presented to an urban pediatric emergency department with moderate to severe pharyngitis.4 Exclusion criteria were similar to the study by Bulloch et al. Patients were then randomized to either receive oral dexamethasone (n=57) 0.6 mg/kg (maximum of 10 mg) or placebo (n=68), and all received a rapid strep test. If the rapid strep was positive, they received either intramuscular penicillin, oral amoxicillin, or oral azithromycin. Negative rapid strep tests were cultured. Primary endpoints were time to inception of pain relief, time to complete resolution of pain, need for further medical care, antipyretic usage, fever, and potential dexamethasone side effects.

A total of 70 children tested positive for GAS—27 in the dexamethasone group and 43 in the placebo group. Similar to the results of Bulloch et al, this study found a shorter time to initial relief of sore throat of 5.1 hours (95 percent confidence interval [CI], 0.5–10.8 hours) when comparing dexamethasone with placebo in the group that was GAS positive. The time to complete relief of sore throat, though, in this same GAS-positive group was not significantly different. For GAS-positive patients, the number was statistically significant but of uncertain clinical significance. Interestingly, the GAS-negative group had a statistically shorter time to initial relief and complete relief of sore throat of 15.3 and 32.9 hours, respectively. It is important to note, though, that the study only included patients with moderate to severe pain. No patients with mild pain were included. For children with strep throat (GAS-positive), oral dexamethasone may only mildly shorten initial pain relief.

The final RCT by Niland et al evaluated a convenience sample of 90 patients ages 4–21 years, comparing GAS-positive patients in both an urgent care and emergency department setting.5 Patients with strep throat by positive rapid strep test were randomized to one of three arms: single oral dexamethasone 0.6 mg/kg dose (maximum of 10 mg) versus three consecutive days of once daily oral dexamethasone 0.6 mg/kg dose (maximum of 10 mg once daily) versus placebo. Primary outcomes included time to improvement/resolution of throat pain, return to general health, and return to normal activity level. All patients enrolled in the study were GAS positive; 45 children received intramuscular penicillin (n=45), and 45 children received oral amoxicillin or oral azithromycin (n=45). Six children were lost to follow-up. The results were reported as hazard ratios (HRs). Comparing one- and three-day regimens of dexamethasone showed no difference. Compared to placebo, single-dose dexamethasone demonstrated improvement of general condition (HR 1.87; 95 percent CI, 1.1–3.2; P=0.001) and improvement in activity level (HR 2.25; 95 percent CI, 1.2–3.93; P<0.001).

A systematic review by Wing et al yielded similar conclusions regarding faster pain relief in GAS-positive patients given oral dexamethasone.6 Another review by Schams et al concluded that “for children with severe symptoms and bacterial pathogens confirmed by rapid streptococcal tests, a single dose of oral dexamethasone can be considered a safe adjunctive treatment with antibiotics.”7 Conversely, the only national guideline we are able to find on this topic is from the Italian panel on pharyngitis in children, which recommends against the use of steroids for pharyngitis, stating “steroids may mask signs or symptoms of underlying severe disease such as lymphomas or other malignancy, potentially leading to a delay in diagnosis.”8 They do not differentiate between GAS-positive and GAS-negative cases in their recommendations.

Pages: 1 2 | Single Page

Topics: DexamethasoneGroup A Strep PharyngitisSteroids

Related

  • Do Steroids Have Benefit in Treating Children With Bacterial Meningitis?

    July 6, 2023 - 0 Comment
  • Two Big Changes in Community Acquired Pneumonia Treatment

    June 8, 2023 - 0 Comment
  • Does Administering Steroids for Cardiac Arrest Lead to Better Neurological Outcomes?

    July 21, 2021 - 0 Comment

Current Issue

ACEP Now: June 2025 (Digital)

Read More

About the Authors

Landon Jones, MD

Dr. Jones is associate professor and pediatric emergency medicine fellowship director at the University of Kentucky Department of Emergency Medicine & Pediatrics in Lexington, Kentucky.

View this author's posts »

Richard M. Cantor, MD, FAAP, FACEP

Dr. Cantor is professor of emergency medicine and pediatrics, director of the pediatric emergency department, and medical director of the Central New York Regional Poison Control Center at Upstate Medical University in Syracuse, New York.

View this author's posts »

One Response to “In Kids with Group A Strep, Do Steroids Shorten Illness Duration, Severity?”

  1. December 13, 2020

    gopala k derebail Reply

    Has there been any study conducted to determine the consequence of GAS, i.e. rheumatic fever and other rheumatic sequale in the two groups?

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603